Bristlecone Medical Group integrates advanced diagnostics, genomics, systems biology, and longitudinal surveillance into a selective, deeply individualized model of care designed for prevention, optimization, and durable risk reduction.
Bristlecone operates as a private medical practice focused on long-horizon health strategy. We do not treat isolated symptoms. We quantify risk, map system-level dysfunction, and intervene with precision—often well before disease would traditionally be identified.
A 12-month, high-touch engagement designed for advanced optimization of healthspan, risk reduction, and performance. Capacity is limited, intended for individuals who expect discretion, clinical rigor, and measurable outcomes.
Selective access to specific therapies for patients requiring focused, efficient care and precisely targeted intervention.
Dr. Kelly Gibas leads a multi-disciplinary clinical team at Bristlecone Medical Group, integrating advanced diagnostics, genomics, systems biology, and longitudinal surveillance into a unified, high-touch clinical strategy. Her work is grounded in precision medicine and defined by restraint—data informs judgment; it does not
The team delivers rigorously constructed, deeply individualized programs for patients seeking advanced evaluation of cardiometabolic risk, hormone optimization, cognitive resilience, inflammatory burden, and performance physiology. The objective is not episodic care, but sustained control of long-term trajectory.
At Bristlecone, this philosophy is operationalized within a selective clinical environment where interpretation carries equal weight to testing, and every intervention is expected to be measurable, defensible, and strategically aligned.
.png)
.svg)
Precision medicine, preventive strategy, metabolic health, cognitive risk, hormone optimization, and performance medicine.
.svg)
Advanced diagnostics integrated with systems-level analysis, longitudinal monitoring, and targeted intervention design.
.svg)
Selective, discreet, high-attention care for patients seeking rigor, depth, and a disciplined long-term medical strategy.
Pattern recognition, trajectory management, and calibrated intervention rather than reactive symptom-based care.
Dr. Kelly Gibas is the Founder and Clinical Director of Bristlecone Medical Group, where she leads a multi-disciplinary clinical team dedicated to precision medicine, systems biology, and proactive disease prevention. Combining advanced diagnostics, genomics, and evidence-based medicine, Dr. Gibas helps patients identify risk early, optimize performance, and improve long-term health outcomes. As a Medical Science Liaison, Research Specialist, and tenured Associate Professor, she combines academic rigor, clinical experience, and a collaborative model of care designed to deliver highly individualized health strategies for each patient.
.png)
.png)
.png)
.png)
Precision medicine, preventive strategy, metabolic health, cognitive risk, hormone optimization, and performance medicine.
Advanced diagnostics integrated with systems-level analysis, longitudinal monitoring, and targeted intervention design.
Selective, discreet, high-attention care for patients seeking rigor, depth, and a disciplined long-term medical strategy.
Pattern recognition, trajectory management, and calibrated intervention rather than reactive symptom-based care.
A curated body of clinical analysis focused on early risk detection, prevention strategy, and longitudinal health architecture. Each insight reflects how data is interpreted and applied in real-world patient care.
A clinical interpretation of lipid discordance and early atherosclerotic signaling. Standard cholesterol testing focuses heavily on LDL-C, but ApoB provides a clearer picture of cardiovascular risk by measuring the number of particles capable of contributing to plaque formation. In many cases, elevated ApoB can reveal risk long before traditional markers raise concern, making it a valuable tool for early prevention and intervention.
A focused interpretation of particle measures, discordance, and metabolic context. ApoB and LDL-P are both used to assess cardiovascular risk, yet they do not always tell the same story. Differences between these measurements can provide important clues about metabolic health, particle composition, and disease progression. Understanding this discordance helps create a more complete risk profile.
Why fasting glucose often lags behind the physiology that drives risk. Insulin resistance often develops years before diabetes is diagnosed and may exist even when glucose levels appear normal. As the body compensates by producing more insulin, metabolic stress begins to build. Early identification allows for targeted lifestyle and clinical interventions that can reduce future disease risk.
Inflammation as a parallel driver of plaque progression and instability. Cardiovascular disease is influenced by more than cholesterol alone. hs-CRP measures systemic inflammation and can uncover hidden risk that remains despite otherwise healthy lipid levels. Monitoring inflammatory markers helps provide a broader understanding of long-term cardiovascular health.
Blood-based signal, structural confirmation, and timing of escalation. Emerging biomarkers such as pTau217 are transforming how clinicians assess neurodegenerative risk. Blood-based testing can provide early insight into underlying pathology and help determine when additional imaging or specialist evaluation may be appropriate, supporting more proactive care decisions.
Why binding proteins determine the meaning of the number. Hormone health cannot be fully understood through total testosterone alone. SHBG plays a critical role in regulating how much hormone is available for use throughout the body. Evaluating both values together provides a more accurate understanding of symptoms, performance, and overall hormonal balance.
Overfed meets undernourished in the pathology of mild cognitive impairment (MCI) and Alzheimer’s disease (AD).
Glucose dependency marks the cancerous phenotype. Austin Diabetes Research, Austin Diabetes Res. 2017; 1(1): 1065.
Syndrome to Alzheimer’s Disease. J Metabolic Synd. 2020;9(1): 001-005. doi:10.37421/JMS.2020.9.251
A clinical interpretation of lipid discordance and early atherosclerotic signaling. Standard cholesterol testing focuses heavily on LDL-C, but ApoB provides a clearer picture of cardiovascular risk by measuring the number of particles capable of contributing to plaque formation. In many cases, elevated ApoB can reveal risk long before traditional markers raise concern, making it a valuable tool for early prevention and intervention.
A focused interpretation of particle measures, discordance, and metabolic context. ApoB and LDL-P are both used to assess cardiovascular risk, yet they do not always tell the same story. Differences between these measurements can provide important clues about metabolic health, particle composition, and disease progression. Understanding this discordance helps create a more complete risk profile.
Why fasting glucose often lags behind the physiology that drives risk. Insulin resistance often develops years before diabetes is diagnosed and may exist even when glucose levels appear normal. As the body compensates by producing more insulin, metabolic stress begins to build. Early identification allows for targeted lifestyle and clinical interventions that can reduce future disease risk.
Inflammation as a parallel driver of plaque progression and instability. Cardiovascular disease is influenced by more than cholesterol alone. hs-CRP measures systemic inflammation and can uncover hidden risk that remains despite otherwise healthy lipid levels. Monitoring inflammatory markers helps provide a broader understanding of long-term cardiovascular health.
Blood-based signal, structural confirmation, and timing of escalation. Emerging biomarkers such as pTau217 are transforming how clinicians assess neurodegenerative risk. Blood-based testing can provide early insight into underlying pathology and help determine when additional imaging or specialist evaluation may be appropriate, supporting more proactive care decisions.
Why binding proteins determine the meaning of the number. Hormone health cannot be fully understood through total testosterone alone. SHBG plays a critical role in regulating how much hormone is available for use throughout the body. Evaluating both values together provides a more accurate understanding of symptoms, performance, and overall hormonal balance.
A clinical interpretation of lipid discordance and early atherosclerotic signaling. Standard cholesterol testing focuses heavily on LDL-C, but ApoB provides a clearer picture of cardiovascular risk by measuring the number of particles capable of contributing to plaque formation. In many cases, elevated ApoB can reveal risk long before traditional markers raise concern, making it a valuable tool for early prevention and intervention.
A focused interpretation of particle measures, discordance, and metabolic context. ApoB and LDL-P are both used to assess cardiovascular risk, yet they do not always tell the same story. Differences between these measurements can provide important clues about metabolic health, particle composition, and disease progression. Understanding this discordance helps create a more complete risk profile.
Why fasting glucose often lags behind the physiology that drives risk. Insulin resistance often develops years before diabetes is diagnosed and may exist even when glucose levels appear normal. As the body compensates by producing more insulin, metabolic stress begins to build. Early identification allows for targeted lifestyle and clinical interventions that can reduce future disease risk.
Inflammation as a parallel driver of plaque progression and instability. Cardiovascular disease is influenced by more than cholesterol alone. hs-CRP measures systemic inflammation and can uncover hidden risk that remains despite otherwise healthy lipid levels. Monitoring inflammatory markers helps provide a broader understanding of long-term cardiovascular health.
Why binding proteins determine the meaning of the number. Hormone health cannot be fully understood through total testosterone alone. SHBG plays a critical role in regulating how much hormone is available for use throughout the body. Evaluating both values together provides a more accurate understanding of symptoms, performance, and overall hormonal balance.
A clinical interpretation of lipid discordance and early atherosclerotic signaling. Standard cholesterol testing focuses heavily on LDL-C, but ApoB provides a clearer picture of cardiovascular risk by measuring the number of particles capable of contributing to plaque formation. In many cases, elevated ApoB can reveal risk long before traditional markers raise concern, making it a valuable tool for early prevention and intervention.
A focused interpretation of particle measures, discordance, and metabolic context. ApoB and LDL-P are both used to assess cardiovascular risk, yet they do not always tell the same story. Differences between these measurements can provide important clues about metabolic health, particle composition, and disease progression. Understanding this discordance helps create a more complete risk profile.
Why fasting glucose often lags behind the physiology that drives risk. Insulin resistance often develops years before diabetes is diagnosed and may exist even when glucose levels appear normal. As the body compensates by producing more insulin, metabolic stress begins to build. Early identification allows for targeted lifestyle and clinical interventions that can reduce future disease risk.
Glucose dependency marks the cancerous phenotype. Austin Diabetes Research, Austin Diabetes Res. 2017; 1(1): 1065.
Inflammation as a parallel driver of plaque progression and instability. Cardiovascular disease is influenced by more than cholesterol alone. hs-CRP measures systemic inflammation and can uncover hidden risk that remains despite otherwise healthy lipid levels. Monitoring inflammatory markers helps provide a broader understanding of long-term cardiovascular health.
Blood-based signal, structural confirmation, and timing of escalation. Emerging biomarkers such as pTau217 are transforming how clinicians assess neurodegenerative risk. Blood-based testing can provide early insight into underlying pathology and help determine when additional imaging or specialist evaluation may be appropriate, supporting more proactive care decisions.
Why binding proteins determine the meaning of the number. Hormone health cannot be fully understood through total testosterone alone. SHBG plays a critical role in regulating how much hormone is available for use throughout the body. Evaluating both values together provides a more accurate understanding of symptoms, performance, and overall hormonal balance.
A clinical interpretation of lipid discordance and early atherosclerotic signaling. Standard cholesterol testing focuses heavily on LDL-C, but ApoB provides a clearer picture of cardiovascular risk by measuring the number of particles capable of contributing to plaque formation. In many cases, elevated ApoB can reveal risk long before traditional markers raise concern, making it a valuable tool for early prevention and intervention.
A focused interpretation of particle measures, discordance, and metabolic context. ApoB and LDL-P are both used to assess cardiovascular risk, yet they do not always tell the same story. Differences between these measurements can provide important clues about metabolic health, particle composition, and disease progression. Understanding this discordance helps create a more complete risk profile.
Why fasting glucose often lags behind the physiology that drives risk. Insulin resistance often develops years before diabetes is diagnosed and may exist even when glucose levels appear normal. As the body compensates by producing more insulin, metabolic stress begins to build. Early identification allows for targeted lifestyle and clinical interventions that can reduce future disease risk.
Inflammation as a parallel driver of plaque progression and instability. Cardiovascular disease is influenced by more than cholesterol alone. hs-CRP measures systemic inflammation and can uncover hidden risk that remains despite otherwise healthy lipid levels. Monitoring inflammatory markers helps provide a broader understanding of long-term cardiovascular health.
Blood-based signal, structural confirmation, and timing of escalation. Emerging biomarkers such as pTau217 are transforming how clinicians assess neurodegenerative risk. Blood-based testing can provide early insight into underlying pathology and help determine when additional imaging or specialist evaluation may be appropriate, supporting more proactive care decisions.
Why binding proteins determine the meaning of the number. Hormone health cannot be fully understood through total testosterone alone. SHBG plays a critical role in regulating how much hormone is available for use throughout the body. Evaluating both values together provides a more accurate understanding of symptoms, performance, and overall hormonal balance.
A clinical interpretation of lipid discordance and early atherosclerotic signaling. Standard cholesterol testing focuses heavily on LDL-C, but ApoB provides a clearer picture of cardiovascular risk by measuring the number of particles capable of contributing to plaque formation. In many cases, elevated ApoB can reveal risk long before traditional markers raise concern, making it a valuable tool for early prevention and intervention.
A focused interpretation of particle measures, discordance, and metabolic context. ApoB and LDL-P are both used to assess cardiovascular risk, yet they do not always tell the same story. Differences between these measurements can provide important clues about metabolic health, particle composition, and disease progression. Understanding this discordance helps create a more complete risk profile.
Why fasting glucose often lags behind the physiology that drives risk. Insulin resistance often develops years before diabetes is diagnosed and may exist even when glucose levels appear normal. As the body compensates by producing more insulin, metabolic stress begins to build. Early identification allows for targeted lifestyle and clinical interventions that can reduce future disease risk.
Inflammation as a parallel driver of plaque progression and instability. Cardiovascular disease is influenced by more than cholesterol alone. hs-CRP measures systemic inflammation and can uncover hidden risk that remains despite otherwise healthy lipid levels. Monitoring inflammatory markers helps provide a broader understanding of long-term cardiovascular health.
Blood-based signal, structural confirmation, and timing of escalation. Emerging biomarkers such as pTau217 are transforming how clinicians assess neurodegenerative risk. Blood-based testing can provide early insight into underlying pathology and help determine when additional imaging or specialist evaluation may be appropriate, supporting more proactive care decisions.
Why binding proteins determine the meaning of the number. Hormone health cannot be fully understood through total testosterone alone. SHBG plays a critical role in regulating how much hormone is available for use throughout the body. Evaluating both values together provides a more accurate understanding of symptoms, performance, and overall hormonal balance.
A clinical interpretation of lipid discordance and early atherosclerotic signaling. Standard cholesterol testing focuses heavily on LDL-C, but ApoB provides a clearer picture of cardiovascular risk by measuring the number of particles capable of contributing to plaque formation. In many cases, elevated ApoB can reveal risk long before traditional markers raise concern, making it a valuable tool for early prevention and intervention.
A focused interpretation of particle measures, discordance, and metabolic context. ApoB and LDL-P are both used to assess cardiovascular risk, yet they do not always tell the same story. Differences between these measurements can provide important clues about metabolic health, particle composition, and disease progression. Understanding this discordance helps create a more complete risk profile.
Why fasting glucose often lags behind the physiology that drives risk. Insulin resistance often develops years before diabetes is diagnosed and may exist even when glucose levels appear normal. As the body compensates by producing more insulin, metabolic stress begins to build. Early identification allows for targeted lifestyle and clinical interventions that can reduce future disease risk.
Inflammation as a parallel driver of plaque progression and instability. Cardiovascular disease is influenced by more than cholesterol alone. hs-CRP measures systemic inflammation and can uncover hidden risk that remains despite otherwise healthy lipid levels. Monitoring inflammatory markers helps provide a broader understanding of long-term cardiovascular health.
Why binding proteins determine the meaning of the number. Hormone health cannot be fully understood through total testosterone alone. SHBG plays a critical role in regulating how much hormone is available for use throughout the body. Evaluating both values together provides a more accurate understanding of symptoms, performance, and overall hormonal balance.
A clinical interpretation of lipid discordance and early atherosclerotic signaling. Standard cholesterol testing focuses heavily on LDL-C, but ApoB provides a clearer picture of cardiovascular risk by measuring the number of particles capable of contributing to plaque formation. In many cases, elevated ApoB can reveal risk long before traditional markers raise concern, making it a valuable tool for early prevention and intervention.
A focused interpretation of particle measures, discordance, and metabolic context. ApoB and LDL-P are both used to assess cardiovascular risk, yet they do not always tell the same story. Differences between these measurements can provide important clues about metabolic health, particle composition, and disease progression. Understanding this discordance helps create a more complete risk profile.
Why fasting glucose often lags behind the physiology that drives risk. Insulin resistance often develops years before diabetes is diagnosed and may exist even when glucose levels appear normal. As the body compensates by producing more insulin, metabolic stress begins to build. Early identification allows for targeted lifestyle and clinical interventions that can reduce future disease risk.
Inflammation as a parallel driver of plaque progression and instability. Cardiovascular disease is influenced by more than cholesterol alone. hs-CRP measures systemic inflammation and can uncover hidden risk that remains despite otherwise healthy lipid levels. Monitoring inflammatory markers helps provide a broader understanding of long-term cardiovascular health.
Why binding proteins determine the meaning of the number. Hormone health cannot be fully understood through total testosterone alone. SHBG plays a critical role in regulating how much hormone is available for use throughout the body. Evaluating both values together provides a more accurate understanding of symptoms, performance, and overall hormonal balance.
Our clinical framework is informed by active contribution to peer-reviewed research and continuous integration of emerging data in metabolic medicine, neurodegeneration, and aging science. What is validated in research is translated into clinical application.
.svg)
Engage a clinical team operating at the leading edge of preventive and performance medicine. All inquiries are reviewed personally. Selective onboarding ensures the highest level of care, fit, and access.
.png)
